DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the NECTAR LIFESCIENCES LTD. (NECLIFE) share price today?

NECTAR LIFESCIENCES LTD. (NECLIFE) is trading at ₹10.85 on the NSE, down 0.46% on the day. Source: DocStoX.

What is the market capitalisation of NECTAR LIFESCIENCES LTD.?

NECTAR LIFESCIENCES LTD. has a market capitalisation of approximately ₹244 crore.

NECTAR LIFESCIENCES LTD.

NECLIFE·NSE·Healthcare

₹10.85▼ -0.05 (-0.46%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹10.52

₹11.19

52W₹9

₹2212%

Open

₹11.10

High

₹11.19

Low

₹10.52

Prev Close

₹10.90

Volume

1.01L

VWAP

₹10.87

Snapshot

Key fundamentals

Market Cap

₹244 Cr

P/E Ratio

N/A

P/B Ratio

0.40

EPS

₹-15.08

Book Value

₹30.00

ROE

-7.46%Weak

ROCE

-5.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹1.00

52W High

₹22.40

52W Low

₹9.30

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹23

▲ 112.0%upside

Trading at ₹11 — 112% below our estimate

BearFair valueBull

₹20₹23₹26

/100

Business quality — Watch the fundamentals

Growth 0Profitability 0Efficiency 0Valuation 100

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Weak returns on equity (-7%)

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Weak returns on equity (-7%)
Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

-7% ROE fading to 12% over ~3 yrs, on ₹30 book

₹23

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹23

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Weak returns on equity (-7%)
Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-7.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

-5.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹244 Cr

P/B

0.40

EPS

₹-15.08

Div Yield

—

What changed

Recent changes

Domestic institutions+0.5% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Shrinking

-89% rev CAGR

Profitability

Loss-making

-7.5% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹10.97L Cr

Trades342

VWAP₹10.87

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-89.0%

-73.5%

10Y

-49.0%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 0.37 times its book value
Promoter holding has increased by 6.93% over last quarter.

Watch-outs

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -73.5% over past five years.
Company has a low return on equity of -5.83% over last 3 years.
Contingent liabilities of Rs.134 Cr.
Working capital days have increased from 8,908 days to 26,618 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions added 0.47 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

51.8%0.00

Public

36.2%+0.40

FII / FPI

0.6%+0.02

DII

4.0%+0.47

Others

7.3%

Total shareholders

74,834-1,814 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter51.84%

FII0.60%

DII4.01%

Government0.02%

Public36.23%

Others7.30%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]